In subgroup analyses, for NSCLC, SCLC, ICIs only without combination with chemotherapy or target therapy, anti-PD-1/PD-L1 plus anti-CTLA-4, the magnitude of efficacy of ICIs was greater for patients without LM than patients with LM, and the heterogeneity test for this LM-related interaction was significant. The gene discussed is CTLA4; the disease is small cell lung carcinoma.